Akebia Ther (AKBA)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
AKBA
Akebia Ther
$0.50
-13.20%
HEALTHCARE · Cap: $195.78M
TAK
Takeda Pharmaceutical Co Ltd ADR
$21.12
+1.34%
HEALTHCARE · Cap: $67.16B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 2142343% more annual revenue ($4.69T vs $219.06M). TAK leads profitability with a 0.9% profit margin vs -13.5%. TAK earns a higher WallStSmart Score of 56/100 (C).
AKBA
Avoid24
out of 100
Grade: F
TAK
Buy56
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Growing faster than its price suggests
Reasonable price relative to book value
Generating 212.6B in free cash flow
Large-cap with strong market position
Strong operational efficiency at 24.5%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -74.9% — below average capital efficiency
ROE of 5.2% — below average capital efficiency
0.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 9.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : AKBA
AKBA has a balanced fundamental profile.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bear Case : AKBA
The primary concerns for AKBA are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.16 is elevated, increasing financial risk.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, Profit Margin, P/E Ratio. A P/E of 300.3x leaves little room for execution misses. Thin 0.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
AKBA profiles as a turnaround stock while TAK is a value play — different risk/reward profiles.
AKBA carries more volatility with a beta of 0.18 — expect wider price swings.
TAK is growing revenue faster at 6.7% — sustainability is the question.
TAK generates stronger free cash flow (212.6B), providing more financial flexibility.
Bottom Line
TAK scores higher overall (56/100 vs 24/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Akebia Ther
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?